Asset Details
Do you wish to reserve the book?
Polydopamine Nanoparticle‐Mediated Dopaminergic Immunoregulation in Colitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Polydopamine Nanoparticle‐Mediated Dopaminergic Immunoregulation in Colitis
Do you wish to request the book?
Polydopamine Nanoparticle‐Mediated Dopaminergic Immunoregulation in Colitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Polydopamine Nanoparticle‐Mediated Dopaminergic Immunoregulation in Colitis
2022
Overview
Despite immunosuppression is critical for reducing immune overactivation, existing immunosuppressive agents are largely restricted by low inhibition efficiencies and unpredictable off‐target toxicities. Here, the use of the dopaminergic system is reported to suppress hyperactive immune responses in local inflamed tissues. A polydopamine nanoparticular immunosuppressant (PDNI) is synthesized to stimulate regulatory T (Treg) cells and directly inhibit T helper 1 (Th1), Th2, and Th17 cells. Moreover, PDNI can inhibit the activation of dendritic cells to upregulate the ratio of Treg/Th17, which assists the reversion of inflammatory responses. The application of dopaminergic immunoregulation is further disclosed by combining with gut microbiota modulation for treating inflammations. The combination is implemented by coating living beneficial bacteria with PDNI. Following oral delivery, coated bacteria not only suppress the hyperactive immune responses but also positively modulate the gut microbiome in mice characterized with colitis. Strikingly, the combination demonstrates enhanced treatment efficacies in comparison with clinical aminosalicylic acid in two murine models of colitis. The use of the dopaminergic system opens a window to intervene immune responses and provides a versatile platform for the development of new therapeutics for treating inflammatory diseases. The dopaminergic system is reported to suppress hyperactive immune responses in local inflamed tissues by a polydopamine nanoparticular immunosuppressant, which can stimulate regulatory T lymphocytes and dendritic cells, while directly inhibit T helper cells. The application of dopaminergic immunoregulation is further disclosed by combining with oral probiotics that can modulate the gut microbiota for treating colitis.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
